A poor metabolizer for cytochromes P450 2D6 and 2C19: a case report on antidepressant treatment.

• Abstract: Scientific literature has never described a poor metabolizer for both the cytochrome P450 (CYP) 2D6 and the CYP 2C19. They are expected to be rare (<1% in different ethnic groups) and prone to adverse drug reactions with many antidepressants. In an ongoing pharmacogenetic study, after genotyping 1,576 subjects in three Kentucky state hospitals we have found one poor metabolizer for both CYP 2D6 and CYP 2C19, which corresponds to a prevalence of 0.06% (95% CI 0.01 to 0.36). The naturalistic antidepressant treatment of this poor metabolizer for both enzymes is described in this article. As genotyping reaches clinical practice, it will be interesting to prospectively establish whether mirtazapine is a reasonable choice as an antidepressant for these patients, as the data and this case suggest.
• Authors: Maria Johnson, Courtney Markham-Abedi, Margaret T Susce, Elaina Murray-Carmichael, Stuart McCollum, Jose de Leon (Affiliation: University of Kentucky Mental Health Research Center, Eastern State Hospital, Lexington, KY 40508, USA.)
• Journal: CNS spectrums (CNS Spectr) Vol. 11 Issue 10 Pg. 757-60 (Oct 2006) ISSN: 1092-8529 [Print] United States
• PMID: 17008819 (Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)

Chemical References

• Antidepressive Agents
• Mixed Function Oxygenases
• Aryl Hydrocarbon Hydroxylases
• CYP2C19 protein, human
• Cytochrome P-450 CYP2D6

Topics

• Antidepressive Agents (adverse effects, pharmacokinetics)
• Aryl Hydrocarbon Hydroxylases (metabolism)
• Cytochrome P-450 CYP2D6 (metabolism)
• Depressive Disorder, Major (drug therapy, epidemiology)
• Female
• Gene Expression (genetics)
• Genotype
• Humans
• Metabolic Diseases (epidemiology, metabolism)
• Middle Aged
• Mixed Function Oxygenases (metabolism)